-10%
Barif 40mg Tablet
Barif tablets are indicated for the chronic management of hyperuricemia in patients with gout
:
Out of stock
In stock – ready to ship
Delivery
Inside Dhaka: 1–2 days · Outside Dhaka: 2–4 days
Cash on Delivery
Pay when you receive your order.
Returns
Easy 7-day return & exchange
- Category
- Tablet & Capsules
- Brand
- Square Pharmaceuticals PLC
Product details
Barif 40mg Tablet
Barif tablets are indicated for the chronic management of hyperuricemia in patients with gout. Barif tablets are not recommended for the treatment of asymptomatic hyperuricemia.
Pharmacology
Febuxostat is a non-purine, selective xanthine oxidase (XO) inhibitor. It decreases serum uric acid level by inhibiting xanthine oxidase, which is responsible for uric acid production. Xanthine oxidase breaks down hypoxanthine to xanthine and thus to uric acid. Febuxostat is not expected to inhibit other enzymes involved in purine and pyrimidine synthesis and metabolism at therapeutic concentrations.
Contraindications
Febuxostat is contraindicated in patients being treated with azathioprine, mercaptopurine, or theophylline.
side Effects
The most commonly reported adverse reactions are gout flares, liver function abnormalities, diarrhoea, nausea, headache, rash and oedema. These adverse reactions were mostly mild or moderate in severity. Rare serious hypersensitivity reactions to Barif have observed.
Pregnancy & Lactation
Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Febuxostat should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether this drug is excreted in human milk. Caution should be exercised when Febuxostat is administered to a nursing woman.
Precautions & Warnings
Gout Flare: An increase in gout flares is frequently observed during initiation of anti-hyperuricemic agents, including Barif. If a gout flare occurs during treatment, Barif need not be discontinued. Prophylactic therapy (i.e., non-steroidal anti-inflammatory drug (NSAID) or colchicine upon initiation of treatment) may be beneficial for up to six months.
Cardiovascular Events: A higher rate of cardiovascular thromboembolic events was observed in patients treated with Barif than allopurinol in clinical trials. Monitor for signs and symptoms of MI and stroke.
Liver Enzyme Elevation: Transaminase elevations have been observed in Barif -treated patients. Monitor liver function tests periodically.
Overdose Effects
Febustat was studied in healthy subjects in doses up to 300 mg daily for seven days without evidence of dose-limiting toxicities.
Therapeutic Class
Drugs used in Gout
Storage Conditions
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.
0 reviews
⭐
No reviews yet
Bought this product? Share your experience to help others.
You may also like
Recently viewed
Barif 40mg Tablet
৳360